+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness of the RGn600 device in treating patients with mild-to-moderate Alzheimers disease. This device combines PhotoBioModulation, which uses light from red to near-infrared wavelengths, and Static Magnetic Stimulation to potentially reduce inflammation on the brain-gut axis involved in Alzheimers development. The study is a randomized, double-blind, sham-controlled trial conducted at multiple centers in France. Participants will be randomly assigned to use either the active RGn600 device or an inactive sham device. The device is applied non-invasively as a helmet on the head and an abdominal belt, with treatment sessions lasting 20 minutes each. Treatment is scheduled for 5 sessions per week during weeks 1 to 8, 3 sessions per week from weeks 9 to 16, and 2 sessions per week from weeks 17 to 26. After the treatment phase, participants will be followed for up to 52 weeks. Throughout the study, participants will attend four onsite visits to assess cognition, autonomy, quality of life, and safety through neurological tests, questionnaires, clinical exams, and blood samples. Additional biological samples such as fecal and saliva will be collected at one site for further analysis. Researchers will track changes in cognitive scores using the ADAS-cog scale and monitor adverse events and device safety. The study aims to understand the impact of RGn600 treatment over one year.

Age: 55Years - 85YearsAll GendersPhase Not Applicable
7 locations